Teva Q2 2023 revenue $3.88B, GAAP loss $0.77/sh, non-GAAP EPS $0.56; raises revenue guidance

TEVA PHARMACEUTICAL INDUSTRIES LTD

2023-Q2 EPS reported -$0.96 revenue$7,539,000,000

Revenue $3.88B (+2% YoY, +4% local currency); AUSTEDO U.S. rev $308M.
GAAP net loss $863M ($0.77 loss per share) vs $232M loss in Q2 2022.
Non-GAAP diluted EPS $0.56, down from $0.68 YoY; non-GAAP operating margin 26.1%.
Free cash flow $632M; operating cash flow $324M.
FY 2023 revenue guidance raised to $15.0-$15.4B; all other guidance reaffirmed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended June 30, 2023 results: revenue $3,878 million, EPS GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56. Guidance reaffirmed.

Period: the quarter ended June 30, 2023
Revenue: $3,878 million
EPS: GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56
Guidance: reaffirmed
Result: reported results

Exact text from the filing

structure, while also reorganizing key business units to enhance operational efficiency. Second Quarter 2023 Consolidated Results Revenues in the second quarter of 2023 were $3,878 million, an increase of 2% compared to the second quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from AUSTEDO and Anda in our North

View on SEC.gov

Browse all earnings releases →

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001157523-23-001212

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.